1. Emergence of novel long-acting mono- and bi-specific IL-2/IL-13 superkines as potent immune modulators. (October 2020) Authors: Merchant, F.; To, M.; Merchant, R. Journal: European journal of cancer Issue: Volume 138(2020)Supplement 2 Page Start: S57 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. MDNA132 is an IL-13 Superkine selective to IL-13Rα2 with broad potential for delivery of immunotherapies to the tumor microenvironment. (October 2022) Authors: Sharma, A.; To, M.; Gobeil, P.; Merchant, F. Journal: European journal of cancer Issue: Volume 174(2022)Supplement 1 Page Start: S127 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. MDNA55, a Locally Administered IL4 Guided Toxin for Targeted Treatment of Recurrent Glioblastoma Shows Long Term Survival Benefit. (October 2020) Authors: Sampson, J.; Achrol, A.S.; Aghi, M.K.; Bankiewicz, K.; Bexon, M.; Brem, S.; Brenner, A.; Chowdhary, S.; Coello, M.; Ellingson, B.M.; Floyd, J.R.; Han, S.; Kesari, S.; Merchant, F.; Merchant, N.; Randazzo, D.; Vogelbaum, M.; Vrionis, F.; Zabek, M.; Butowski, N. Journal: European journal of cancer Issue: Volume 138(2020)Supplement 2 Page Start: S6 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗